Sol-Gel Signs $ 27 M Deal for Dermatology Drug Delivery

Sol-Gel Signs $ 27 M Deal for Dermatology Drug Delivery

Ness Ziona, Israel, February 20, 2012 / B3C newswire / - Sol-Gel Technologies Ltd. announced today that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug.

Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of an initial non-refundable payment as well as additional license fees and development payments upon the successful completion of various milestones. The U.S. partner will fund the product’s development. Sol-Gel will be entitled to receive royalties from net sales.

The new agreement follows a similar $25 million deal made with the same company.

“This repeat collaboration reinforces Sol-Gel’s position as a leading player in the development of encapsulation technologies for application to topical drug products,” said Dr. Alon Seri-Levy, co-founder and CEO.

About Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a private specialty pharmaceutical company based in Ness Ziona, Israel. The company develops novel drugs for the dermatology market and provides state-of-the-art solutions and lifecycle management opportunities for dermatological companies.

Sol-Gel’s patented drug delivery system enhances the efficacy, safety and stability of topical drugs by encapsulating the drug substances in an inert, clear-silica microcapsule shell and by releasing the active pharmaceutical ingredients in a time-controlled manner. The technology enables Sol-Gel to offer the derma market advanced topical drug products that are more effective and/or have fewer side effects than existing drugs.

“Sol-Gel is maximizing its value by creating a diverse proprietary product pipeline with high market potential and by collaborating with global pharmaceutical companies,” commented Gil Bianco, Chairman of Sol-Gel.

Sol-Gel’s pipeline includes an innovative topical therapy for rosacea known as DER45-EV Gel currently undergoing a Phase II multi-center study in the U.S.; a new generation of anti-acne kits, targeting the $1 billion acne therapy market; and other dermatology products that have been significantly improved by Sol-Gel’s proprietary drug delivery technology.

Sol-Gel was founded in 1997 to commercialize a breakthrough technology developed by co-founder Prof. David Avnir of the Hebrew University of Jerusalem.
Sol-Gel has been funded by a distinguished group of Israeli and international investors, including Medica (Israel), JVP (Israel), Argonaut (US), DSM (Netherlands), Challenge (Israel), Evergreen (Israel), Millenium (Israel) and Jesselson (US).

Alon Seri-Levy, CEO
Sol-Gel Technologies Ltd.
7 Golda Meir St.
Weizmann Science Park
Ness Ziona 74036, Israel
Tel:  +972-8-9313433

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.